Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 4 | 2024 | 261 | 1.420 |
Why?
|
| Biomarkers, Tumor | 8 | 2025 | 524 | 1.210 |
Why?
|
| Head and Neck Neoplasms | 5 | 2023 | 166 | 1.050 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 408 | 0.820 |
Why?
|
| Epidermal Growth Factor | 2 | 2020 | 49 | 0.740 |
Why?
|
| Lung Neoplasms | 4 | 2025 | 704 | 0.710 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 75 | 0.640 |
Why?
|
| Melanoma | 4 | 2025 | 333 | 0.540 |
Why?
|
| Saliva | 1 | 2017 | 100 | 0.520 |
Why?
|
| Mutation | 3 | 2024 | 2658 | 0.510 |
Why?
|
| Circulating Tumor DNA | 3 | 2020 | 10 | 0.490 |
Why?
|
| Lipids | 1 | 2017 | 328 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2025 | 509 | 0.430 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2025 | 730 | 0.400 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2024 | 10 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2025 | 583 | 0.380 |
Why?
|
| MicroRNAs | 4 | 2024 | 710 | 0.360 |
Why?
|
| Trisomy | 1 | 2012 | 22 | 0.360 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 54 | 0.350 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 1222 | 0.330 |
Why?
|
| Cisplatin | 3 | 2022 | 147 | 0.320 |
Why?
|
| Gene Expression Profiling | 5 | 2025 | 794 | 0.310 |
Why?
|
| Mouth Neoplasms | 2 | 2023 | 41 | 0.310 |
Why?
|
| Brazil | 4 | 2025 | 103 | 0.300 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 1566 | 0.290 |
Why?
|
| Paclitaxel | 2 | 2019 | 102 | 0.270 |
Why?
|
| Telomerase | 2 | 2024 | 30 | 0.250 |
Why?
|
| Transcriptome | 3 | 2025 | 399 | 0.250 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 62 | 0.250 |
Why?
|
| Humans | 27 | 2025 | 65124 | 0.240 |
Why?
|
| ErbB Receptors | 3 | 2025 | 127 | 0.230 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 644 | 0.230 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 1 | 2025 | 3 | 0.230 |
Why?
|
| CD24 Antigen | 1 | 2025 | 18 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 128 | 0.220 |
Why?
|
| Genotype | 3 | 2025 | 673 | 0.210 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2023 | 5 | 0.200 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2023 | 6 | 0.200 |
Why?
|
| Carcinoma, Papillary | 1 | 2023 | 37 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 197 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2025 | 274 | 0.190 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 87 | 0.180 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 286 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 318 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 128 | 0.170 |
Why?
|
| Middle Aged | 11 | 2025 | 18267 | 0.170 |
Why?
|
| Female | 15 | 2025 | 34016 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 513 | 0.170 |
Why?
|
| Prognosis | 5 | 2025 | 1785 | 0.170 |
Why?
|
| Alleles | 2 | 2019 | 453 | 0.160 |
Why?
|
| Male | 13 | 2025 | 31042 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1141 | 0.160 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 24 | 0.160 |
Why?
|
| Sentinel Lymph Node | 1 | 2020 | 12 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 184 | 0.160 |
Why?
|
| Pharmacogenomic Variants | 1 | 2019 | 3 | 0.150 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 27 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 44 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 354 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 205 | 0.150 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2020 | 120 | 0.150 |
Why?
|
| Melanins | 1 | 2019 | 24 | 0.150 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 61 | 0.150 |
Why?
|
| Genetics, Population | 1 | 2019 | 45 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2019 | 122 | 0.140 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 89 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 464 | 0.130 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2017 | 3 | 0.130 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 17 | 0.130 |
Why?
|
| Aged | 6 | 2025 | 14958 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 1 | 2017 | 49 | 0.130 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2016 | 12 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2020 | 418 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 493 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 687 | 0.120 |
Why?
|
| Adult | 6 | 2025 | 17356 | 0.120 |
Why?
|
| Risk Factors | 3 | 2025 | 5429 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1575 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5788 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1630 | 0.100 |
Why?
|
| Mice | 2 | 2025 | 11105 | 0.100 |
Why?
|
| Infant | 2 | 2024 | 1693 | 0.100 |
Why?
|
| Testicular Neoplasms | 2 | 2024 | 35 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2025 | 94 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 218 | 0.090 |
Why?
|
| Disorders of Sex Development | 1 | 2012 | 12 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5612 | 0.090 |
Why?
|
| Karyotype | 1 | 2012 | 18 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2012 | 23 | 0.090 |
Why?
|
| Microcephaly | 1 | 2012 | 15 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 373 | 0.090 |
Why?
|
| Cell Movement | 2 | 2025 | 480 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 101 | 0.080 |
Why?
|
| Self Report | 2 | 2023 | 391 | 0.080 |
Why?
|
| Disease Progression | 3 | 2020 | 1219 | 0.080 |
Why?
|
| Animals | 2 | 2025 | 21324 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 244 | 0.070 |
Why?
|
| Phenotype | 1 | 2012 | 1232 | 0.070 |
Why?
|
| Adolescent | 3 | 2024 | 6305 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2019 | 754 | 0.060 |
Why?
|
| Fibronectins | 1 | 2025 | 44 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2025 | 287 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 24 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 90 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 60 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 361 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 60 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 22 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 107 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 182 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 178 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 132 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 215 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2025 | 1036 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 5 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 35 | 0.040 |
Why?
|
| Tryptophan | 1 | 2020 | 56 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2020 | 49 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 65 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 51 | 0.040 |
Why?
|
| Lymphoscintigraphy | 1 | 2020 | 6 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2020 | 11 | 0.040 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2020 | 39 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 64 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 39 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2020 | 35 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2020 | 50 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2020 | 69 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6862 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 169 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 44 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2019 | 16 | 0.040 |
Why?
|
| Centrifugation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 232 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2025 | 2619 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2024 | 2061 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 302 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 544 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 587 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 367 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 852 | 0.030 |
Why?
|
| Mouth | 1 | 2016 | 35 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 414 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2017 | 129 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 415 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 739 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2020 | 918 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 930 | 0.030 |
Why?
|
| Child | 1 | 2024 | 4612 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 483 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 896 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1113 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3310 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1698 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3762 | 0.020 |
Why?
|